Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387500 | 0.86 | NPY5R (0.42) | TDP1NPY5RKMT2AMEN1POLB | |
| SCHEMBL5387497 | 0.86 | NPY5R (0.42) | TDP1NPY5RKMT2AMEN1POLB | |
| SCHEMBL3918722 | 0.84 | ALDH1A1 (0.45) | NPY5RKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL7470115 | 0.83 | NPY5R (0.34) | TDP1NPY5RKMT2AMEN1POLB | |
| SCHEMBL5382919 | 0.80 | ALDH1A1 (0.38) | TDP1NPY5RKMT2AMEN1POLB | |
| SCHEMBL5131843 | 0.80 | ALDH1A1 (0.38) | TDP1NPY5RKMT2AMEN1POLB | |
| SCHEMBL1960773 | 0.78 | — | — | |
| SCHEMBL5382478 | 0.78 | TDP1 (0.38) | TDP1 | |
| SCHEMBL5392388 | 0.73 | ALDH1A1 (0.51) | KMT2AMEN1POLBALDH1A1CYP2C9 | |
| SCHEMBL12313412 | 0.72 | NPY5R (0.41) | NPY5RKMT2AMEN1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273880-B2 | Selective NPY (Y5) antagonists | H. LUNBECK A/S (DK) | 2007-09-25 | — | — | US | disclosed |
| EP-1194421-B1 | SELECTIVE NPY (Y5) ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2005-10-12 | — | — | EP | disclosed |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-06-23 | — | — | US | disclosed |
| US-6222040-B1 | FOR THERAPY OF EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137240-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | TDP1 3169/4885NPY5R 1/4885KMT2A 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.